王帅 郑宪玲

    【摘要】? 钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是近年来发现的一类新型的非胰岛素依赖性口服降糖药，代表药物包括达格列净、恩格列净、卡格列净等。临床上，糖尿病肾病(DKD)大多起病隐匿，早期并无明显症状，患者往往在出现水肿、泡沫尿等症状后才会就诊，此时多数患者已经进入不可逆阶段，治疗手段有限且效果欠佳。临床上通过检测超敏C反应蛋白、视黄醇结合蛋白等指标可以辅助早期诊断DKD。早期合理应用SGLT2i可以预防DKD的发生与发展，使糖尿病患者最大程度的获益。

    【关键词】? 钠-葡萄糖共转运蛋白2抑制剂；糖尿病肾病；超敏C反应蛋白；视黄醇结合蛋白

    中图分类号? R587.2? ? 文献标识码? A? ? 文章编号? 1671-0223(2024)01--05

    Research progress on the relationship between SGLT2i and serum hs-CRP and RBP in patients with diabetic kidney disease Wang Shuai， Zheng Xianling. Chengde Medical University， Chengde 067000， China

    【Abstract】? Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new class of non-insulin-dependent oral hypoglycemic drugs discovered in recent years， representative drugs include dapagliflozin， empagliflozin， canagliflozin， etc. Clinically， diabetic kidney disease(DKD) has many insidious onset， no obvious symptoms in the early stage， patients often appear after edema， foamy urine and other symptoms before visiting the doctor， at this time most patients have entered the irreversible stage， treatment methods are limited and the effect is not good. By detecting hypersensitive C-reactive protein ......